Capricor Therapeutics has delivered a very large 3 year gain, yet the stock now screens as overvalued on market multiples and earns a mixed valuation score, so the recent pullback raises questions about how much of the story is already reflected in the price.

• Capricor Therapeutics has returned about 4.4x over the past 3 years, which puts extra focus on whether the current share price leaves enough room for disappointment.
• The upcoming FDA review and PDUFA decision for Deramiocel can be a key driver of expectations, while recent insider share sales ahead of these events may add to perceived risk around the approval outcome.
• With a 4 out of 6 valuation score, Capricor Therapeutics presents a mixed picture rather than a clear bargain or a clearly expensive stock on the broader checks.

The stock's next move may depend on whether Capricor Therapeutics' current price already reflects the potential of Deramiocel or still offers room for investors to be compensated for the risks ahead.

Does Capricor Therapeutics Look Pricey on Book Value?

Price to book is a useful cross check for Capricor Therapeutics because it is still in a development heavy phase where book value and cash on hand matter more than current earnings. Capricor trades at a P/B of about 4.8x, which is higher than the broader Biotechs sector average of roughly 2.8x, but slightly below the peer group average of about 5.5x.

On this yardstick the stock screens overvalued versus the typical biotech, indicating investors are paying a richer price for each dollar of equity than the sector overall. The upcoming FDA advisory committee review and PDUFA decision for Deramiocel help explain why expectations are elevated. However, the current P/B already reflects a premium that could limit upside if sentiment cools after these events.

Overall, Capricor Therapeutics appears overvalued on the P/B multiple, with the share price already assigning a premium to its balance sheet compared with the wider biotech sector.

The Capricor Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Capricor Therapeutics pick up where the valuation puzzle leaves off by spelling out which paths for revenue, margins and earnings would have to unfold for Capricor Therapeutics' stock to be worth materially more or less than it is today. Each Narrative ties a fair value estimate to a particular set of potential catalysts and risks, so you can track over time which version of Capricor Therapeutics' story seems closest to reality on the Community page.

One of the top community narratives on Capricor Therapeutics: 58% undervalued

"Capricor's strong cash position, combined with the potential to receive a priority review voucher and an $80M milestone payment upon approval, provides a cushion to minimize dilution risk and support commercial launch…"

Do you think there's more to the story for Capricor Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

For Capricor Therapeutics, the current market multiples suggest a stock where expectations are already set high. The mixed valuation score indicates that this is not a clear-cut bargain, but also not an extreme outlier against peers on every metric. From here, the key question is whether the outcome and commercial potential around Deramiocel ultimately support the premium investors are currently paying, or whether any disappointment on that front leads the multiple to move closer to the broader biotech sector.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.